Payment overview · 2025
General Payments
$1,166.99
69 reported records · 17 companies
Healthcare provider profile · identity verified
Christopher L Shelby, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BILOXI, MS · NPI 1851333009
Verified facts
What the public records show
CMS Open Payments records show Christopher L Shelby, M.D. received $1,166.99 in general payments during 2025 across 69 reported records.
PFIZER INC. accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $197.35 | 16.9% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.25 | 13.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $154.11 | 13.2% | 13 | 2025 |
| Sight Sciences, Inc. | Unresolved — no canonical attribution shown | $140.33 | 12.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $75.48 | 6.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.89 | 5.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.74 | 5.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.16 | 4.9% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $53.39 | 4.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $51.58 | 4.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.17 | 3.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.66 | 2.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.03 | 2.1% | 1 | 2025 |
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $21.94 | 1.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.41 | 1.2% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.96 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.54 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,166.99 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $197.35 | 22 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $154.11 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.09 | 2 | 2025 |
Source payment records
|
|||||
| OMNI SURGICAL SYSTEM Normalized: omni surgical system |
Device | Sight Sciences, Inc. | $140.33 | 1 | 2025 |
Source payment records
|
|||||
| SION SURGICAL INSTRUMENT Normalized: sion surgical instrument |
Device | Sight Sciences, Inc. | $140.33 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $104.34 | 11 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $75.48 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.16 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $53.39 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $51.58 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.28 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.96 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.17 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.91 | 2 | 2025 |
Source payment records
|
|||||
| Titan Normalized: titan |
Device | COLOPLAST CORP | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 583 | 173 |
| Amlodipine Besylate | Amlodipine Besylate | 476 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 373 | 104 |
| Lisinopril | Lisinopril | 349 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 262 | 91 |
| Metformin Hcl | Metformin Hcl | 228 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 195 | 52 |
| Omeprazole | Omeprazole | 190 | 61 |
| Losartan Potassium | Losartan Potassium | 181 | 60 |
| Simvastatin | Simvastatin | 162 | 43 |
| Fluoxetine Hcl | Fluoxetine Hcl | 143 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 143 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 35 |
| Metformin Hcl Er | Metformin Hcl | 121 | 37 |
| Trazodone Hcl | Trazodone Hcl | 120 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 31 |
| Gabapentin | Gabapentin | 100 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 32 |
| Furosemide | Furosemide | 98 | 36 |
| Famotidine | Famotidine | 95 | 30 |
| Allopurinol | Allopurinol | 94 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 28 |
| Montelukast Sodium | Montelukast Sodium | 92 | 25 |
| Carvedilol | Carvedilol | 90 | 27 |
| Valsartan | Valsartan | 90 | 29 |
| Potassium Chloride | Potassium Chloride | 88 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 34 |
| Tramadol Hcl | Tramadol Hcl | 78 | 19 |
| Ozempic | Semaglutide | 73 | 19 |
| Atenolol | Atenolol | 72 | 18 |
| Eliquis | Apixaban | 69 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 19 |
| Clonazepam | Clonazepam | 67 | 13 |
| Meloxicam | Meloxicam | 67 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 67 | 15 |
| Fenofibrate | Fenofibrate | 66 | 17 |
| Irbesartan | Irbesartan | 64 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 23 |
| Sertraline Hcl | Sertraline Hcl | 59 | 19 |
| Alendronate Sodium | Alendronate Sodium | 58 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 26 |
| Glipizide | Glipizide | 49 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 12 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | 12 |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 14 |
| Ramipril | Ramipril | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 11 |
| Alprazolam | Alprazolam | 36 | 17 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 11 |
| Finasteride | Finasteride | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 11 |
| Celecoxib | Celecoxib | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 16 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Azithromycin | Azithromycin | 19 | 19 |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Topiramate | Topiramate | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,166.99 · 69 records | PFIZER INC. | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, GEMTESA, KISUNLA, Kerendia, Korlym, MOUNJARO, NURTEC ODT, NUZYRA, OMNI SURGICAL SYSTEM, Ozempic, Qelbree, SION SURGICAL INSTRUMENT, SPRAVATO, TRELEGY ELLIPTA, Titan, UBRELVY, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error